Royce & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,340	Closed	-$235K	–	993
2021 Q2	$235K	Sell	5,340 -592	-10%	-$29K	﹤0.01%	980
2021 Q1	$293K	Sell	5,932 -4,748	-44%	-$237K	﹤0.01%	984
2020 Q4	$450K	Buy	10,680 +170	+2%	+$7.48K	﹤0.01%	903
2020 Q3	$481K	Buy	10,510 +32	+0.3%	+$1.55K	0.01%	867
2020 Q2	$526K	Buy	10,478 +136	+1%	+$7.04K	0.01%	853
2020 Q1	$532K	Buy	10,342 +3,062	+42%	+$163K	0.01%	821
2019 Q4	$450K	Buy	7,280 +3,597	+98%	+$223K	﹤0.01%	902
2019 Q3	$221K	Buy	3,683 +3,403	+1,215%	+$253K	﹤0.01%	974
2019 Q2	$24K	Buy	280 +5	+2%	+$450	﹤0.01%	1102
2019 Q1	$26K	Sell	275 -13	-5%	-$1.17K	﹤0.01%	1104
2018 Q4	$20K	Buy	288 +25	+10%	+$1.92K	﹤0.01%	1106
2018 Q3	$22K	Buy	263 +141	+116%	+$14.1K	﹤0.01%	1147
2018 Q2	$14K	Buy	122 +17	+16%	+$1.7K	﹤0.01%	1181
2018 Q1	$8K	Sell	105 -83	-44%	-$6.39K	﹤0.01%	1207
2017 Q4	$11K	Buy	+188	New	+$9.41K	﹤0.01%	1166